Affiliation:
1. From the Department of Biomedical Sciences, Creighton University, Omaha, NE.
Abstract
Congenital blood disorders are common and yet clinically challenging globin disorders. Gene therapy continues to serve as a potential therapeutic method to treat these disorders. While tremendous advances have been made in vivo, gene delivery protocols and vector prototypes still require optimization. Alternativecis-acting promoter elements derived from VL30 retroelements have been effective in expressing tissue-specific transgene expression in vivo in nonerythroid cells. VL30 promoter elements were isolated from ELM-I-1 erythroid progenitor cells upon erythropoietin (epo) treatment. These promoters were inserted into a VL30-derived expression vector and reintroduced into the ELM-I-1 cells. β-Galactosidase reporter gene activity from the ELM 5 clone, a BVL-1–like VL30 promoter, was capable of expressing sustained levels of the transgene expression over a 16-week assay period. These findings delineate the potential utility of these retroelement promoters as transcriptionally active, erythroid-specific, long terminal repeat (LTR) components for current globin vector constructs.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference25 articles.
1. Murine gene therapy corrects symptoms of sickle cell disease.;Wilson;Scientist.,2002
2. Therapeutic haemoglobin synthesis in β-globin.;May;Nature.,2000
3. Correction of sickle cell disease in transgenic mouse models by gene therapy.;Pawliuk;Nature.,2001
4. Toward gene therapy for disorders of globin synthesis.;Tisdale;Semin Hematol.,2001
5. Long-term expression of γ-globin mRNA in mouse erythrocytes from retrovirus vectors containing the human γ-globin gene fused to the ankyrin-1 promoter.;Sabatino;Proc Natl Acad Sci U S A.,2000